Additionally, in the PrECOG 0105 phase 2 trial (NCT00813956), clinical responses of wild-type BRCA1/2 breast cancer to cisplatin patients were higher in patients classified as HRD defined as a LOH score ≥10 [4]. This evidence concerns the gene BRCA1 and breast carcinoma.